Barinthus Biotherapeutics Plc Stock Performance
| BRNS Stock | 0.95 0.02 2.06% |
The firm shows a Beta (market volatility) of 1.2, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Barinthus Biotherapeutics will likely underperform. At this point, Barinthus Biotherapeutics has a negative expected return of -0.33%. Please make sure to confirm Barinthus Biotherapeutics' total risk alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Barinthus Biotherapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Barinthus Biotherapeutics plc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
1 | Barinthus Biotherapeutics appoints new COO - Investing.com | 09/05/2024 |
2 | Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer | 10/01/2024 |
3 | Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results | 11/06/2024 |
4 | Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion | 11/15/2024 |
5 | Barinthus Biotherapeutics shares hold Buy rating as analyst sees strong VTP-300 results | 11/19/2024 |
6 | Acquisition by Scheeren Joseph of 19516 shares of Barinthus Biotherapeutics at 2.34 subject to Rule 16b-3 | 11/21/2024 |
7 | Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer | 11/25/2024 |
| Begin Period Cash Flow | 194.4 M |
Barinthus |
Barinthus Biotherapeutics Relative Risk vs. Return Landscape
If you would invest 132.00 in Barinthus Biotherapeutics plc on August 30, 2024 and sell it today you would lose (37.00) from holding Barinthus Biotherapeutics plc or give up 28.03% of portfolio value over 90 days. Barinthus Biotherapeutics plc is currently does not generate positive expected returns and assumes 5.864% risk (volatility on return distribution) over the 90 days horizon. In different words, 52% of stocks are less volatile than Barinthus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Barinthus Biotherapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Barinthus Biotherapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Barinthus Biotherapeutics plc, and traders can use it to determine the average amount a Barinthus Biotherapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0556
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BRNS |
Estimated Market Risk
| 5.86 actual daily | 52 52% of assets are less volatile |
Expected Return
| -0.33 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Barinthus Biotherapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Barinthus Biotherapeutics by adding Barinthus Biotherapeutics to a well-diversified portfolio.
Barinthus Biotherapeutics Fundamentals Growth
Barinthus Stock prices reflect investors' perceptions of the future prospects and financial health of Barinthus Biotherapeutics, and Barinthus Biotherapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Barinthus Stock performance.
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.19 | ||||
| Operating Margin | (0.61) % | ||||
| Current Valuation | (55.02 M) | ||||
| Shares Outstanding | 40.23 M | ||||
| Price To Book | 0.24 X | ||||
| Price To Sales | 2.57 X | ||||
| Revenue | 802 K | ||||
| Gross Profit | 44.7 M | ||||
| EBITDA | (74.81 M) | ||||
| Net Income | (73.45 M) | ||||
| Total Debt | 12.98 M | ||||
| Book Value Per Share | 4.03 X | ||||
| Cash Flow From Operations | (50.92 M) | ||||
| Earnings Per Share | (1.49) X | ||||
| Market Capitalization | 38.41 M | ||||
| Total Asset | 214.51 M | ||||
| Retained Earnings | (176.59 M) | ||||
| Working Capital | 144.31 M | ||||
About Barinthus Biotherapeutics Performance
Assessing Barinthus Biotherapeutics' fundamental ratios provides investors with valuable insights into Barinthus Biotherapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Barinthus Biotherapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.41) | (0.43) | |
| Return On Capital Employed | (0.42) | (0.44) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | (0.39) | (0.37) |
Things to note about Barinthus Biotherapeutics performance evaluation
Checking the ongoing alerts about Barinthus Biotherapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Barinthus Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Barinthus Biotherapeutics generated a negative expected return over the last 90 days | |
| Barinthus Biotherapeutics has high historical volatility and very poor performance | |
| Barinthus Biotherapeutics has some characteristics of a very speculative penny stock | |
| Barinthus Biotherapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 802 K. Net Loss for the year was (73.45 M) with profit before overhead, payroll, taxes, and interest of 44.7 M. | |
| Barinthus Biotherapeutics generates negative cash flow from operations | |
| Barinthus Biotherapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer |
- Analyzing Barinthus Biotherapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Barinthus Biotherapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Barinthus Biotherapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Barinthus Biotherapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Barinthus Biotherapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Barinthus Biotherapeutics' stock. These opinions can provide insight into Barinthus Biotherapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Barinthus Stock Analysis
When running Barinthus Biotherapeutics' price analysis, check to measure Barinthus Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Barinthus Biotherapeutics is operating at the current time. Most of Barinthus Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Barinthus Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Barinthus Biotherapeutics' price. Additionally, you may evaluate how the addition of Barinthus Biotherapeutics to your portfolios can decrease your overall portfolio volatility.